Merrill rates MedImmune neutral

MedImmune Inc. was given a neutral rating by Merrill Lynch analyst Eric Ende after the company reported third-quarter revenue and earnings per share in line with estimates. The company raised its 2006 earnings per share guidance to $0.17, from $0.22, due to the impact of gains from the sale of a portfolio company (Avidia) and payment of a $70 million milestone to Infinity. MedImmune's revenue guidance is unchanged. In addition ,the company officially canceled its Abegrin program for melanoma, which was not in the analyst's model. Shares of the Gaithersburg, Md.-based biotechnology company were up 45 cents, or 1.51%, at $30.20. (Nasdaq: MEDI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.